Metformin ameliorates endometrial thickness in a rat model of thin endometrium
Clinical and Experimental Pharmacology and Physiology · 2024
DOI: 10.1111/1440-1681.13862 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Pharmacology and Physiology, 2024. Verfasst von M Imran und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cell Physiology and Pathology Laboratory, ICMR-National Institute for Research in Reproductive and Child Health, Mumbai, India. Hauptthemen laut MEDLINE: Metformin, Polycystic Ovary Syndrome. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: The Indian Council of Medical Research, Science and Engineering Research Board.
Abstract (Originalsprache)
Metformin, a well‐established anti‐diabetic drug, is also used in managing various other metabolic disorders including polycystic ovarian syndrome (PCOS). There are evidences to show that metformin improves endometrial functions in PCOS women. However, fewer studies have explored the direct effects of metformin on endometrium. Previous in vitro studies have shown that therapeutic serum concentrations of metformin enhance endometrial epithelial cell proliferation. The present study was undertaken to investigate in vivo effects of metformin on endometrial proliferation in a rat model of thin endometrium. Toward this, a rat model of thin endometrium was developed. Metformin (0.1% or 1% w/v) was administrated orally for 15 days in rats with thin endometrium. Oral metformin administration for three consecutive estrous cycles (15 days) in the thin endometrium rat model led to an increase in endometrial thickness compared to sham endometrium. Histological analysis showed a significant increase in the number of endometrial glands ( P < 0.05), stromal cells ( P < 0.01) and blood vessels ( P < 0.01) in metformin‐treated (n = 10 in each group) uterine horns compared to sham (saline‐treated) uterine horns in rats. The expression of proliferating cell nuclear antigen and vascular epithelial growth factor was found to be upregulated on treatment with 1% metformin‐treated group (n = 7). However, pregnancy outcomes in the rats treated with metformin remained unaltered despite the restoration of endometrial thickness. In conclusion, the study demonstrated that metformin ameliorates endometrial thickness in a rat model of thin endometrium by increasing endometrial proliferation and angiogenesis, without restoration of embryo implantation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cell Physiology and Pathology Laboratory, ICMR-National Institute for Research in Reproductive and Child Health, Mumbai, India.
- Experimental Animal Facility, ICMR-National Institute for Research in Reproductive and Child Health, Mumbai, India.
Förderung
- The Indian Council of Medical Research
- Science and Engineering Research Board
Zitieren
APA
Imran, M., Khandvilkar, A., Metkari, S., Sachdeva, G., & Chaudhari, U. (2024). Metformin ameliorates endometrial thickness in a rat model of thin endometrium. Clinical and Experimental Pharmacology and Physiology. https://doi.org/10.1111/1440-1681.13862
Vancouver
Imran M, Khandvilkar A, Metkari S, Sachdeva G, Chaudhari U. Metformin ameliorates endometrial thickness in a rat model of thin endometrium. Clinical and Experimental Pharmacology and Physiology. 2024. doi:10.1111/1440-1681.13862
BibTeX
@article{Imran2024,
author = {Imran, M and Khandvilkar, Aditya and Metkari, Siddhanath and Sachdeva, Geetanjali and Chaudhari, Uddhav},
title = {Metformin ameliorates endometrial thickness in a rat model of thin endometrium},
journal = {Clinical and Experimental Pharmacology and Physiology},
year = {2024},
doi = {10.1111/1440-1681.13862}
}
EUVIMED